News | December 05, 2021
Eris signs JV with MJ Biopharm to supply insulin in India
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The product will be commercialized from Unichem's Ghaziabad plant
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
One of the very few facilities in India to have this capability, marking a remarkable feat in LifeCell’s expedition to take genome sequencing to the next level in India
Subscribe To Our Newsletter & Stay Updated
